Thiogenesis hires Brisco Capital for investor relations
Thiogenesis Therapeutics said it has engaged Brisco Capital for investor relations. The company is a clinical-stage biotech developing sulfur-based therapeutics for rare diseases.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.